It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...
A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
There is growing competition in the diaper market with Chinese brands entering the US, creating pricing pressure.s. Barclays ...
A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...